FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| [CAR-T cell immunotherapy in early relapse after introduction chemoimmunotherapy]. PMID 41716107 · Recenti Prog Med · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The Effect of Audiovisual Education on Breast Cancer Screening and Fear Among Illiterate Women: A Double-Blind Randomised Controlled Trial. PMID 41709589 · J Eval Clin Pract · 2026-Feb Study is a randomized trial on breast cancer screening education, which is oncology-related and in humans. However, it lacks a drug intervention (the intervention is audiovisual education) and does not report a time-to-event efficacy endpoint. Therefore, it does not meet the core criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial. PMID 41705515 · Mult Scler · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The effect of two remote exercise programs on cardiorespiratory fitness, cardiac function, and vascular health in patients with breast cancer. PMID 41704018 · Physiol Rep · 2026-Feb The study is an oncology RCT in humans reporting original primary results, but it is excluded because: 1) The intervention is exercise-only (no drug-containing intervention), and 2) The endpoint is not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or any analysis involving Kaplan-Meier or HR). The endpoints measured are physiological (VO2peak, biomarkers). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Disparities in Distress Symptoms Among Cancer Inpatients, Outpatients and Relatives Through Introducing and Evaluating Digital Distress Screening. PMID 41689782 · Psychooncology · 2026-Feb The study is a randomized controlled trial in oncology patients, but it evaluates digital screening tools for distress, not a drug intervention. It does not have a Phase III/IIIb or Phase II/III designation. The primary endpoints are distress levels, usability, and acceptance, not time-to-event efficacy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Epilepsy-Desirability of Outcome Ranking (DOOR) as a Multi-Faceted Consumer-Informed Outcome Measure for Epilepsy Clinical Trials. PMID 41665255 · Eur J Neurol · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The clinical and cost-effectiveness of paravertebral blockade versus thoracic epidural blockade in reducing chronic post-thoracotomy pain: TOPIC2 RCT synopsis. PMID 41664616 · Health Technol Assess · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT/WJOG10617G): a randomised phase 2 trial in Japan. PMID 41660367 · EClinicalMedicine · 2026-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Safety and immunogenicity of bivalent RSVpreF vaccine formulated in a multidose vial in healthy female participants in the USA: a multicentre, randomised, open-label, noninferiority phase 3 study. PMID 41660362 · EClinicalMedicine · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Microbiological analysis and whole-genome sequencing of Neisseria gonorrhoeae from the microbiological failures in the international, zoliflodacin, phase 3, clinical trial for treatment of uncomplicated urogenital gonorrhoea: a retrospective, genomic, observational study. PMID 41655579 · Lancet Microbe · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Generalizability of Edaravone Efficacy. PMID 41653008 · Muscle Nerve · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Introduction to the Supplement. PMID 41653006 · Muscle Nerve · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Survival of Intravenous Edaravone-Treated Patients With ALS: Evidence From Administrative Claims Analyses. PMID 41653004 · Muscle Nerve · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Study 19 (MCI186-19) Post Hoc Analyses. PMID 41653003 · Muscle Nerve · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. PMID 41651641 · Lancet Haematol · 2026-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Paclitaxel plus cetuximab for the treatment of R/M SCCHN after first-line pembrolizumab failure: primary analysis from the PaceAce trial. PMID 41650746 · ESMO Open · 2026-Feb The study is an oncology, human, original result with drug intervention and time-to-event endpoints, but it is a single-arm phase II trial (as indicated by the text 'first prospective trial' and the small sample size of 57 patients). It is not randomized and not a Phase III/IIIb or Phase II/III randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Optimizing vedolizumab therapy in ulcerative colitis: A critical synthesis of trial evidence and the emerging role of artificial intelligence. PMID 41642870 · PLOS Digit Health · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Plain language summary of TASUKI-52: A study looking at nivolumab plus platinum chemotherapy and bevacizumab as a combined treatment for people with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC). PMID 41640231 · Future Oncol · 2026-Feb The record is a plain language summary, not a formal results report. The abstract is empty, providing no data on the trial phase, human subjects, time-to-event endpoints, or original result details. The title indicates a randomized study (keyword: 'randomized controlled trial') with a drug intervention, but without a results abstract or full publication, eligibility criteria cannot be established. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Gastric Cancer Mortality-to-Incidence Ratios in Latin America and the Caribbean: A Machine Learning Analysis of Socioeconomic and Clinical Research Predictors. PMID 41637677 · JCO Glob Oncol · 2026-Feb This is a retrospective, country-level epidemiological and research landscape analysis, not a report of a randomized clinical trial with time-to-event efficacy outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| SNF-CLIMEDIN: A Randomized Trial of Digital Support and Intervention in Patients With Advanced Non-Small Cell Lung Cancer. A Hellenic Cooperative Oncology Group Study. PMID 41632937 · JCO Clin Cancer Inform · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Epilepsy journey 2.0 study design and methods: A randomized trial of an executive functioning intervention for adolescents with epilepsy. PMID 41631239 · Contemp Clin Trials Commun · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effect of preoperative inspiratory muscle training combined with education course on postoperative pulmonary complications in high-risk patients with lung cancer after video-assisted thoracoscopic surgery: a randomized controlled trial. PMID 41626065 · Contemp Clin Trials Commun · 2026-Feb The record is an oncology randomized controlled trial with original results (interim analysis), but it fails three key eligibility criteria: 1) The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III, and the interim futility stopping suggests it is not a definitive phase trial. 2) The primary endpoint is postoperative pulmonary complications (a binary, non-time-to-event outcome), not a time-to-event efficacy endpoint like OS, PFS, etc. 3) The intervention is non-drug (inspiratory muscle training and education), not a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Practice changing RCT design and rationale: Abbreviated MRI plus AFP vs. ultrasound plus AFP for HCC surveillance in cirrhosis (PREMIUM study). PMID 41624484 · JHEP Rep · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Therapeutic Equivalence of Eyluxvi (Aflibercept) to Eylea in Neovascular Age-Related Macular Degeneration: ALTERA Trial (Randomized). PMID 41619168 · Ophthalmol Ther · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Novel Botulinum Toxin Type A (Protoxin) in the Treatment of Moderate to Severe Glabellar Lines: A Multicenter, Randomized, Double-Blind, Active-Controlled Phase III Study. PMID 41607140 · Ann Dermatol · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer. PMID 41604817 · ESMO Open · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Distortion in the Communication of Nonsignificant Primary Outcomes: The Spin Strategy in Multiple Sclerosis Trials. PMID 41586489 · Ann Neurol · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of adjunct dexamethasone in adults with herpes simplex virus encephalitis in the UK (DexEnceph): a multicentre, observer-blind, randomised, phase 3, controlled trial. PMID 41579900 · Lancet Neurol · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Phase III Randomized Trial Comparing Efficacy, Safety, and Immunogenicity of ZRC-3285 vs. Eylea® in Patients with Wet Age-Related Macular Degeneration. PMID 41578078 · Ophthalmol Ther · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Feasibility and Implementation of INTERVAL-GAP4: A Global Randomised Controlled Trial of Intense Hybrid-supervised/Self-managed Versus Self-directed Exercise for Metastatic Prostate Cancer. PMID 41561488 · Eur Urol Open Sci · 2026-Feb The report is an original article about a Phase III randomized trial in metastatic prostate cancer. However, it is not eligible because: 1) The intervention is exercise-based, not a drug-containing intervention. 2) The primary efficacy outcomes (survival) are explicitly stated to be reported separately; this paper only reports feasibility and implementation. There is no time-to-event efficacy data (OS, PFS, etc.) presented. |
H
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Cartilage organoids bridging bench to bedside: A steroid-free strategy for early osteoarthritis repair. PMID 41560786 · Mater Today Bio · 2026-Feb The record does not meet the fundamental eligibility criterion of being an oncology study. It is a trial for osteoarthritis, not a human malignant neoplasm. Therefore, it is excluded regardless of other criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Open-Label Study Assessing Relative and Absolute Bioavailability of Oral Camizestrant Formulations and Food Effects in Healthy Postmenopausal Women. PMID 41560336 · Clin Transl Sci · 2026-Feb The record describes a pharmacokinetic/bioavailability study in healthy volunteers, not a Phase III/IIIb or Phase II/III randomized efficacy trial with a time-to-event endpoint in cancer patients. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial. PMID 41548565 · Lancet Oncol · 2026-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Sevoflurane's inhibitory effect on postoperative colorectal cancer cell proliferation. PMID 41546564 · Pak J Pharm Sci · 2026-Feb The record meets criteria for oncology, human subjects, and randomization, but fails on phase (not Phase III/IIIb or definitive Phase II/III), primary endpoint (no time-to-event efficacy endpoint), and drug intervention (anesthetic, not oncology drug). The report is an original result but for a non-eligible study type. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study. PMID 41545648 · Clin Drug Investig · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Brain Amyloid Plaque Levels Affect Clinical Progression in Alzheimer Disease: Assessment of Amyloid PET and Change in CDR-SB Utilizing Semi-Mechanistic Model. PMID 41543367 · CPT Pharmacometrics Syst Pharmacol · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial. PMID 41540105 · Nat Med · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Instructed increase in fear activation during exposure exercises does not enhance treatment effects of cognitive behavioral therapy for panic disorder and agoraphobia. PMID 41539132 · Behav Res Ther · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Clinical effectiveness and safety of total glucosides of paeony as an immunomodulator in patients with refractory oral lichen planus: A multicenter, pragmatic, randomized controlled trial. PMID 41539096 · Phytomedicine · 2026-Feb 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
B
|
仅广召回影子组 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Standardized patient coaching improves therapy persistence in patients with hormone receptor-positive, HER2-negative advanced/metastatic breast cancer treated with abemaciclib. PMID 41534416 · Breast · 2026-Feb Study is randomized and reports a time-to-event endpoint (TTD) for a drug (abemaciclib) in oncology. However, the primary endpoint is adherence persistence (PR24), and the study's intervention is patient coaching, not a drug itself. The report does not explicitly confirm Phase III/IIIb or Phase II/III status, which is required for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase II Open-Label Randomised Controlled Trial Comparing Oxaliplatin and Cisplatin Based Concurrent Chemoradiotherapy in Locally Advanced Head and Neck Cancers. PMID 41529317 · Clin Oncol (R Coll Radiol) · 2026-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat. PMID 41526614 · Leukemia · 2026-Feb The record describes a subgroup/biomarker analysis of a Phase 3 randomized trial. While the study is oncologic, human, randomized, and drug-interventional, the reported endpoint (RBC-TI duration, clonal burden) is not a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR analysis as required by the adjudication criteria. Therefore, it is not eligible for the KM digitization cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and network meta-analysis. PMID 41520595 · Lung Cancer · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial. PMID 41520567 · Gynecol Oncol · 2026-Feb The report is an eligible Phase III randomized trial in oncology with time-to-event endpoints, but it lacks a drug-containing intervention (it compares surgical procedures). Therefore, it does not meet all inclusion criteria. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Chewing gum versus heat therapy for postoperative recovery in patients undergoing gynecologic oncology surgery: A randomized controlled trial. PMID 41518771 · Eur J Oncol Nurs · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Sentinel node mapping with carbon nanoparticles versus lymphadenectomy in early cervical cancer. PMID 41512771 · Int J Gynecol Cancer · 2026-Feb The trial is a randomized oncology study with a time-to-event efficacy endpoint, but it does not meet the required drug intervention criterion. The intervention is a surgical technique and a diagnostic mapping agent (carbon nanoparticles), which is not considered a systemic drug therapy for the purposes of this cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Scoping Review Focused on Cooperative Group Involvement in Surgical Randomized Controlled Trials. PMID 41512694 · J Surg Res · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Safety of 48 months of elagolix with add-back therapy for endometriosis-associated pain. PMID 41503019 · AJOG Glob Rep · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of highly purified ethyl icosapentate soft capsules (MND-21) for the treatment of severe hypertriglyceridemia: A 12-week, multi-center, placebo-controlled, randomized, double-blind, phase III clinical trial in China. PMID 41500861 · J Clin Lipidol · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials. PMID 41500083 · Lung Cancer · 2026-Feb The record is a biomarker analysis (subgroup) from two randomized trials (OAK and POPLAR). While the underlying trials are likely Phase III, the phase is not explicitly established in the provided metadata. More critically, this is not the original formal result report of a Phase III/IIIb or Phase II/III trial; it is a secondary, exploratory, or post-hoc analysis focusing on biomarker prognostication and predictive value. The original primary or key secondary time-to-event efficacy endpoint report (e.g., OS, PFS) for the drug intervention (atezolizumab vs. chemotherapy) is not the subject of this paper. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |